Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume Lucid Diagnostics Announces Record Quarterly EsoGuard Test Volume PR Newswire NEW YORK, July 23, 2024 Quarterly EsoGuardtest volume...
Lucid Diagnostics Launches New Corporate Website Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK, July 11, 2024 NEW YORK, July 11, 2024 /PRNewswire/ -- Lucid Diagnostics...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population...
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute PAVmed Subsidiary...
PAVmed Provides Business Update and First Quarter 2024 Financial Results PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Lucid strengthens...
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13...
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall PR Newswire NEW...
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors Lucid Diagnostics Closes Series B / B-1 Preferred Stock...
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024 PR Newswire NEW YORK, May 3, 2024 Conference...